Velinotamig (BCMAxCD3 T cell engager): Treatment-refractory autoimmune diseases driven by long-lived plasma cells (Yahoo Finance) - Jun 10, 2026 - "In the first two patients with refractory SLE...both patients experienced rapid and marked reductions in SLEDAI-2K scores and proteinuria and both achieved complete renal response: SLEDAI-2K scores were 16 and 14 at baseline, respectively, and at the latest follow-up at week 8 were 0 and 2, respectively; Clinical improvements correlated with pharmacodynamic changes consistent with the mechanism of action of velinotamig...Additional multi-dose regimen data in patients with SLE from the Genrix Bio clinical trial in China expected to be shared in Q4 2026; Cullinan plans to initiate a Phase 1/2a clinical trial in Q1 2027 in patients with autoimmune cytopenias, including immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA), autoantibody-mediated diseases with high unmet need."
New P1/2 trial • P1 data • Autoimmune Hemolytic Anemia • Immune Thrombocytopenic Purpura • Systemic Lupus Erythematosus
|